Compare

Swiss Re AG/€SREN

1D1W1M3M6MYTD1Y5YMAX

About Swiss Re AG

Swiss Re AG is a global reinsurance company based in Zurich, Switzerland. It operates primarily in the reinsurance industry, offering both traditional reinsurance products and insurance-based capital market solutions. The company’s core segments include Property & Casualty Reinsurance, Life & Health Reinsurance, and Corporate Solutions, which provides commercial insurance tailored for large and midsize corporations. Founded in 1863, Swiss Re has built a long-standing reputation for absorbing complex risks globally. It maintains a diverse geographic footprint, serving customers and clients across the Americas, Europe, Asia Pacific, and other regions. Swiss Re's strategic positioning is supported by its strong capital base, extensive risk knowledge, and a commitment to developing innovative risk management solutions.
Ticker
€SREN
Sector
Finance
Primary listing
XGAT
Employees
14,522
Headquarters
Zurich, Switzerland
Website
www.swissre.com

Swiss Re AG Metrics

BasicAdvanced
€47B
11.06
€14.83
0.30
€6.83
4.16%

Bulls say / Bears say

Swiss Re earned USD 4.2 billion in the first nine months, up 3%, with a 22.5% return on equity. It remains on track for its USD 4.5 billion full-year profit target. (Swiss Re)
The estimated solvency ratio was 259%, above Swiss Re’s 200–250% target range, and the company had almost completed its USD 1.5 billion share buyback by the end of October. This gives it a strong capital buffer and supports shareholder returns. (Swiss Re)
Rising insured exposures and changing hazards are expected to lift natural catastrophe losses by around 5–7% a year over the long term. That points to growing demand for reinsurance protection and risk expertise. (Swiss Re)
Competitive conditions are weighing on P&C Re: nine-month profit fell 6% and insurance revenue fell 9%. New business CSM, a measure of expected profit on newly written contracts, dropped from USD 2.5 billion to USD 1.8 billion. (Swiss Re)
Recent earnings benefited from lower-than-expected catastrophe losses, but large losses reached USD 941 million in the first nine months, including USD 624 million in the third quarter. Increasing catastrophe exposure leaves results vulnerable to a more severe loss period. (Swiss Re, Swiss Re)
Life & Health Re’s profit rose 43%, helped by favourable US mortality experience, while its new business CSM fell to USD 488 million from USD 833 million. Fewer large deals and selective writing could make it harder to sustain that earnings growth. (Swiss Re)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.